Pazdur R - Search Results

1

Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R. Johnson JR, et al. Among authors: pazdur r. Clin Cancer Res. 2003 Jun;9(6):1972-9. Clin Cancer Res. 2003. PMID: 12796358 Clinical Trial.

2

Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.

Cohen MH, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson JR, O'Leary JJ, White RM, Williams GA, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Oncologist. 2001;6(1):4-11. doi: 10.1634/theoncologist.6-1-4. Oncologist. 2001. PMID: 11161223 Free article.

3

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R. Bross PF, et al. Among authors: pazdur r. Clin Cancer Res. 2001 Jun;7(6):1490-6. Clin Cancer Res. 2001. PMID: 11410481

4

Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.

Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Clin Cancer Res. 2002 Mar;8(3):665-9. Clin Cancer Res. 2002. PMID: 11895893

5

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Clin Cancer Res. 2002 May;8(5):935-42. Clin Cancer Res. 2002. PMID: 12006504

6

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. Dagher R, et al. Among authors: pazdur r. Clin Cancer Res. 2002 Oct;8(10):3034-8. Clin Cancer Res. 2002. PMID: 12374669 Clinical Trial.

7

Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.

Cohen MH, Moses ML, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Oncologist. 2002;7(5):390-2. doi: 10.1634/theoncologist.7-5-390. Oncologist. 2002. PMID: 12401900 Free article.

8

U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.

Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher NS, Sokol GH, Williams GA, Pazdur R. Cohen MH, et al. Among authors: pazdur r. Oncologist. 2002;7(5):393-400. doi: 10.1634/theoncologist.7-5-393. Oncologist. 2002. PMID: 12401901 Free article.

9

FDA drug approval summaries: fulvestrant.

Bross PF, Cohen MH, Williams GA, Pazdur R. Bross PF, et al. Among authors: pazdur r. Oncologist. 2002;7(6):477-80. doi: 10.1634/theoncologist.7-6-477. Oncologist. 2002. PMID: 12490735 Free article.

10

Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.

Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Hoff PM, et al. Among authors: pazdur r. Clin Cancer Res. 2003 Jan;9(1):134-42. Clin Cancer Res. 2003. PMID: 12538461 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

603 results

Search Page

Filters